CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 3,605 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01062074
NCT01062074N/ACompleted

Re-examination Study for General Vaccine Use to Assess the Safety Profile of GARDASIL in Usual Practice

Merck Sharp & Dohme LLC·observational·Posted Feb 4, 2010·Updated Apr 17, 2017

In Brief

An observational study for Human Papillomavirus (HPV) Infection. Completed, enrolled 3,605 participants.

Detailed Summary

This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the clinical usefulness of Gardasil through collecting the safety information according to the Re-examination Regulation for New Drugs.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 4, 2010
Enrollment StartSep 28, 2007
Primary CompletionMay 7, 2013
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 16.4 years ago